Skip to main content
. 2022 Oct 10;13:928945. doi: 10.3389/fimmu.2022.928945

Figure 4.

Figure 4

Concentration of antibodies to β2 adrenergic receptors (anti-β2AdR): (A) Healthy control (donors) and ME/CFS patients. (B) Regarding women and men of both groups. (C) Regarding ME/CFS severity; numbers above graphs show p-value, determined by Mann–Whitney test (A) or Kruskal–Wallis test with respective post-test (B, C). (D, E) ROC analysis showing the potential of anti-β2AdR as a discriminating marker for ME/CFS.